What are the recent advances in the management of antiphospholipid syndrome (APS)?

Recent Advances in Antiphospholipid Syndrome Management

The most significant recent advances in APS include the 2023 ACR/EULAR classification criteria, updated laboratory diagnostic guidance emphasizing mandatory lupus anticoagulant testing, recognition that vitamin K antagonists remain superior to DOACs for most patients, and emerging understanding of thromboinflammatory pathways that may enable future targeted therapies. 1, 2

Diagnostic Advances

New 2023 ACR/EULAR Classification Criteria

• The 2023 criteria represent a major update from the 2006 Sydney criteria, achieving 99% specificity but only 84% sensitivity, explicitly designed for research rather than clinical diagnosis 3
• Critical expansion includes new clinical domains: thrombocytopenia, cardiac valve disease, and microvascular thrombosis are now recognized features 3
• Fixed titer thresholds are now set at 40 Units for moderate and 80 Units for high titers, abandoning the 99th percentile cutoff approach 1
• The criteria distinguish between classification (for research homogeneity) versus day-to-day clinical diagnosis, which requires broader application 1

Laboratory Testing Updates (2025 ISTH Guidance)

• Lupus anticoagulant (LA) positivity is mandatory for identifying high-risk triple-positive patients and informs prognosis and management decisions 1
• Two parallel tests are required: dilute Russell's viper venom time (dRVVT) AND LA-sensitive activated partial thromboplastin time (APTT) 1
• Omitting either dRVVT or APTT increases underdiagnosis risk by up to 55% in triple-positive samples and 31% in APS patients 1
• Each prolonged screening test must be followed by simultaneous mixing and confirmatory testing to detect phospholipid-dependent inhibitors 1
• LA testing during vitamin K antagonist therapy produces false negatives and requires repeat testing with appropriate documentation 1
• Anticardiolipin and anti-β2GPI measurement remains restricted to ELISA methodology 1

Emerging Antibody Testing

• Anti-domain I beta2-glycoprotein I (aDI) antibodies and antiphosphatidylserine/prothrombin antibodies show promise but are not yet incorporated into standard criteria 1
• Anti-β2 glycoprotein I antibodies are now recognized as the critical pathogenic driver triggering cell-specific inflammatory and thrombotic pathways 4

Pathophysiology Advances

Thromboinflammatory Mechanisms

• APS is now understood as a thrombo-inflammatory disease rather than purely thrombotic, driven by antiphospholipid antibodies recognizing phospholipid surfaces and binding proteins 1, 5
• New therapeutic targets identified within the innate immune system include complement activation, neutrophil extracellular traps (NETs), platelet activation, monocyte and endothelial cell activation, and type I interferon pathways 5, 6
• Pro-inflammatory cytokine and chemokine production contributes to disease pathogenesis beyond traditional coagulation mechanisms 6

Management Advances

Anticoagulation Strategy

• Vitamin K antagonists (VKAs) remain the mainstay and appear superior to direct oral anticoagulants (DOACs) for most patients with thrombotic APS 5, 7
• Some guidelines now support DOAC use in specific circumstances, though this remains controversial and requires careful patient selection 2
• Heparin/low molecular weight heparin (LMWH) combined with aspirin improves pregnancy outcomes in obstetric APS 2

Risk-Stratified Approach

• Primary thrombosis prophylaxis should use risk stratification rather than uniform treatment 2
• Triple-positive patients (LA + anticardiolipin + anti-β2GPI) represent the highest risk group requiring aggressive management 1
• Persistent single-positive LA carries lower thrombotic risk than triple positivity but still requires monitoring 1

Phenotype-Specific Management

• Recognition of distinct clinical phenotypes (thrombotic, obstetric, microvascular, catastrophic) enables more targeted approaches 8, 2
• Microvascular and catastrophic APS remain the most challenging, often requiring immunosuppressive agents beyond anticoagulation, though definitive evidence for specific regimens is lacking 2
• Extra-criteria manifestations (thrombocytopenia, cardiac valve disease, nephropathy) are increasingly recognized and incorporated into management decisions 3

Obstetric Management

• Careful monitoring with aspirin plus heparin/LMWH forms the foundation of pregnancy management 2
• Individualized obstetric care protocols improve outcomes but require multidisciplinary coordination 2

Future Therapeutic Directions

Emerging Treatments

• Definitive disease control will likely require strategies that eliminate or neutralize pathogenic antibodies rather than just preventing thrombosis 4
• Novel pharmacological agents targeting diverse thromboinflammatory pathways beyond anticoagulation are under investigation 2
• Immunomodulatory treatments are receiving increased attention as potential adjuncts or alternatives to anticoagulation alone 5

Research Priorities

• The current "one size fits all" management approach needs replacement with pathophysiology-informed subphenotyping and personalized treatment strategies 8
• Better identification of mechanistic drivers of disease heterogeneity is critical for unlocking proactive, personalized treatments 5
• The unmet need for evaluating agents beyond anticoagulants that target specific inflammatory pathways remains a priority 2

Critical Clinical Pitfalls

• Never rely on a single LA test (either dRVVT or APTT alone), as this misses up to 55% of high-risk patients 1
• Avoid LA testing during VKA therapy or in the setting of coagulation factor deficiency, as false negatives are common 1
• Do not conflate classification criteria (designed for research specificity) with clinical diagnosis, which requires broader application to prevent undertreating at-risk patients 1, 3
• The 2023 criteria's high specificity (99%) means some patients with genuine APS may not meet classification thresholds but still require treatment 3
• Persistent antibody positivity (12 weeks apart) remains essential for diagnosis; single positive tests are insufficient 1